MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


AOTI swings to interim profit as Medicaid segment boosts top line

ALN

AOTI Inc on Monday said it sees unprecedented headwinds becoming tailwinds for the business, as it said it remains on track to meet its revised full-year guidance.

AOTI is an Oceanside, California-based wound healing-focused medical technology company.

The company swung to a pretax profit of $788,000 for the six months that ended June 30, from a $3.7 million loss a year prior.

Driving the improved bottom line was a 21% revenue gain to $31.8 million from $26.3 million, as AOTI noted growth across all market segments, but primarily in the Medicaid segment.

Medicaid revenue rose 57% to $14.0 million from $8.9 million, while Veterans Administration improved 2.4% to $17.3 million from $16.9 million.

Other revenue edged 0.7% higher to $544,000 from $540,000.

Looking to the second half, AOTI said it remains on track to deliver on its revised full-year guidance. It expects revenue growth in the mid-teens, and adjusted earnings before interest, tax, depreciation and amortisation margin in the low double digits.

In 2024, these figures were $58.4 million and 13.8% respectively.

‘The company continues to view current US headwinds as transitional, and we remain firmly focused on executing our growth strategy and restoring historical momentum in the medium term,’ said AOTI.

Shares in AOTI were 11% lower at 40.00 pence on Monday morning in London.

Chief Executive Mike Griffiths commented: ‘Performance for the first half of 2025 saw growth across all segments as we continue to build awareness and adoption of our cost and limb saving TWO2 therapy. We are prioritising our commercial execution to the main revenue generating opportunities, while strategically investing in the drivers that will allow for accelerated growth in the mid-term.

‘AOTI is uniquely positioned to deliver effective cost-saving outcomes and clinical data-driven care which aligns with the US Administration’s stated healthcare priorities. Consequently, we believe that the unprecedented headwinds we have been experiencing recently will ultimately turn into tailwinds for our business.’

Copyright 2025 Alliance News Ltd. All Rights Reserved.